Journal Pre-proof

Antibody-coated microbiota in nasopharynx of healthy individuals and hypogammaglobulinemia patients.

Pedro Goncalves, PhD, Bruno Charbit, MSc, Christelle Lenoir, MSc, the Milieu Interieur Consortium, Darragh Duffy, PhD, Alain Fischer, MD, PhD, James P. Di Santo, MD, PhD

PII: S0091-6749(20)30036-1

DOI: <https://doi.org/10.1016/j.jaci.2020.01.002>

Reference: YMAI 14366

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 24 October 2019

Revised Date: 2 January 2020

Accepted Date: 7 January 2020

Please cite this article as: Goncalves P, Charbit B, Lenoir C, the Milieu Interieur Consortium, Duffy D, Fischer A, Di Santo JP, Antibody-coated microbiota in nasopharynx of healthy individuals and hypogammaglobulinemia patients., *Journal of Allergy and Clinical Immunology* (2020), doi: <https://doi.org/10.1016/j.jaci.2020.01.002>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

***Antibody-coated microbiota in nasopharynx of healthy individuals
and hypogammaglobulinemia patients.***

Short title: Ig coated bacteria in the human nasopharynx

Pedro Goncalves, PhD^{1,2}, Bruno Charbit, MSc³, Christelle Lenoir MSc⁴, the Milieu Interieur Consortium, Darragh Duffy, PhD^{2,3,5}, Alain Fischer MD, PhD^{4,6,7,8} and James P Di Santo, MD, PhD^{1,2}.

¹Innate Immunity Unit, Institut Pasteur, Paris, France

²Institut National de la Santé et de la Recherche Médicale (INSERM) U1223, Paris, France

³Center for Translational Research, Institut Pasteur, Paris 75015, France

⁴Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Paris, France.

⁵Laboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Paris 75015, France

⁶University Paris Descartes Sorbonne Paris Cité, Imagine Institut, Paris, France.

⁷Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

⁸Collège de France, Paris, France.

***Corresponding author:** Prof. James P Di Santo, MD, PhD, Innate Immunity Unit, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris, France.; phone: +33-0145688209; e-mail: james.di-santo@pasteur.fr

Capsule summary: We show that nasopharyngeal microbiota are coated by different immunoglobulin isotypes in healthy individuals and with IgG in X-linked agammaglobulinemia (XLA) patients treated with immunoglobulin replacement therapy.

Key Words: human nasopharynx microbiota; antibody-coated microbiota; sIgA; sIgM; IgD; IgG; healthy; X-linked (Bruton's) agammaglobulinemia patients; Immunoglobulin (IgG) replacement therapy; microbiota dysbiosis.

Disclosure of potential conflict of interest:

The authors declare that they have no relevant conflicts of interest.

To the Editor:

Respiratory diseases are important causes of death, which collectively account for more than 1 in 10 of all deaths worldwide (WHO). Pathobionts, potential pathogenic bacteria which under normal circumstances are present as harmless microorganisms, can be found embedded in the nasopharyngeal commensal microbiota. Interestingly, the upper airway microbiome composition seems very similar to that of the lung, and pathobionts present in the nasopharynx can be a primary source of lower respiratory tract infections¹. Several elements participate in respiratory mucosal barrier against invasive pathobionts including the commensal microbiota and glands that secrete and create an antimicrobial mucus barrier containing antimicrobial peptides, immunoglobulins and other soluble factors. Secretory immunoglobulin A (sIgA) and sIgM are transported through nasopharynx epithelial cells by polymeric Ig receptor (pIgR), and IgG by neonatal FcR (FcRn). Transepithelial transport of IgD has not been documented, but IgD is found in nasopharynx secretions² perhaps deriving from paracellular diffusion through cell junctions.

sIgA is the predominant antibody isotype in human nasopharyngeal secretions and it is assumed that the majority of sIgA targets the resident commensal microbiota, inhibiting their penetration via agglutination within the mucus layer, thereby reinforcing commensalism and increasing microbiota diversity³. High-affinity sIgA appears to neutralize microbial toxins and invasive pathogens in the absence of complement fixation³. Interestingly, Fadallah *et al*⁴ reported recently that Selective IgA Deficiency (SIgADef) patients display mild dysbiosis with expansion of some pathobiont species in their feces as compared to healthy controls, although these patients are not abnormally susceptible to intestinal infections⁴. On the other

hand, recurrent pulmonary infections constitute the most prevalent comorbidity in SIgADef patients⁴, suggesting that sIgA may have tissue-specific roles in immune defense, especially in the respiratory tract. A better understanding of immunoglobulins coating nasopharynx microbiota in healthy individuals could provide an important basis for the prevention of respiratory illnesses in some cases of humoral immunodeficiency.

To better understand the role for IgA (and other Ig isotypes) in regulating nasopharyngeal microbial communities, we analyze nasopharyngeal samples to detect Ig-bound microbes followed by 16S ribosomal RNA (rRNA) sequencing (Ig-seq) to determine the type of bacteria targeted by each Ig isotype. We stained nasopharyngeal samples with anti-human IgA, IgM, IgD and IgG antibodies and measured the immunoglobulin-bound populations using a flow cytometer-based assay⁵. The gating strategy for immunoglobulin staining of human nasopharynx microbiota is shown in Fig E1 (all methods are described in the Methods section in this article's Online Repository at www.jacionline.org). On average, a majority of the nasopharynx microbiota appears targeted by sIgA in healthy subjects (Fig E1A), although the frequency of sIgA⁺ microbes is highly variable between individuals (Fig E1B). Next we performed flow sorting of IgA-bound nasopharyngeal microbiota followed by 16S rRNA sequencing (IgA-seq) on a fraction of samples (n=4) (Fig E2A). Beta diversity shows the extent of difference in microbiota community composition from different environments or conditions. The beta diversity, based on Bray-Curtis distance matrix and subjected to Principle Coordinate Analysis, suggest that bacteria derived from IgA⁺ and IgA⁻ fractions cluster distinctly, however, permutational multivariate analysis of variance (PERMANOVA) of the two fractions was not significantly different (Fig E2A, B). The alpha diversity and the Shannon Diversity Index (a combined measure of evenness and number of bacteria) was lightly decreased in 16S rRNA sequences derived from IgA⁻ fraction (Fig E2C). However, both IgA⁺ and IgA⁻ fractions exhibited equal distributions of rare and abundant genera and thus IgA appears to target nasopharyngeal commensals irrespective of their frequency (Fig E2D). These results suggest that under homeostatic conditions, sIgA bind to a broad repertoire of bacteria present in nasopharyngeal microbiota including both commensals and pathobionts³.

Most SIgADef patients have a mild clinical phenotype⁴, which may result from the ability of other Ig isotypes to functionally replace IgA. Increased IgD⁺IgM⁻ B cell populations and increased soluble IgD levels have been described in healthy human upper respiratory mucosa². Therefore, even if IgM and IgD have the same V region and the same antigen specificity, nasopharynx/respiratory B cells apparently switch from IgM to secrete IgD,

suggesting some functional advantage of the latter. The IgD hinge region linking is longer and more flexible than that of IgM thereby facilitating IgD binding to antigens at lower concentrations and in immune complexes². Still, sIgM binds some residual bacteria in the nasopharynx (Fig E1), suggesting that IgM may participate in microbiota agglutination in the steady-state. On the other hand, we found that a vast majority (86%) of the nasopharynx microbiota is targeted by secreted IgD in healthy individuals (Fig E1). We observed that up to 60% of nasopharynx microbiota are double SIgA⁺IgD⁺ coated (Fig 1A, B). We performed flow sorting to isolate IgD-bound microbiota and 16S rRNA sequencing to identify the microbes specifically targeted by IgD (Fig 1C). The IgD⁺ SIgA⁻ fraction showed a higher microbial diversity as compared to SIgA⁺IgD⁻ (Fig 1D). The beta diversity based on Bray-Curtis distances was also different (Fig 1E), suggesting that IgD bind specifically to bacteria not targeted by SIgA. IgD⁺SIgA⁻ fraction exhibited an enrichment in *Proteobacteria* phyla (including *Haemophilus* and *Moraxella* genus) and the pathobionts *Pseudomonas* and *Escherichia-Shigella* (Fig 1F). Previous studies showed that IgD somatic hypermutation (SHM) frequencies are correlated with higher rates of upper respiratory infection⁶, suggesting that pathobiont exposures drive SHM of antigen experienced IgD⁺ B cells. Our results suggest that IgD can recognize a diverse array of both commensal and pathobiont bacteria inhabiting the human upper respiratory mucosa in a manner similar to sIgA. SIgADef patients have increase in IgD-producing B cells in the upper respiratory mucosa and increased IgD secretion², our results are consistent with the notion that IgD may provide a layer of mucosal protection during IgA deficiency.

Several studies demonstrated that mice and human IgG can react to conserved commensal antigens and coat both commensal and pathogenic bacteria⁷. However, Fadallah *et al.*,⁵ recently showed that almost no bacteria in healthy human feces were coated with IgG. Despite the “absence” of IgG coated bacteria in feces, IgG present in serum of these individuals recognizes a wide range of commensals under homeostatic conditions⁵. In addition, SIgADef patients have a increased anti-commensal IgG response⁵. The reduction in IgG coated bacteria in feces does not exclude the possibility that IgG coated bacteria can be present within gut mucus, because IgG have the ability to attach to mucus proteins (e.g. mucin-bound IgG Fc binding protein)⁸. Significant quantities of IgG are secreted and detected within the mucus layer of human respiratory tract and we found that approximately 70% of the microbiota present in nasopharynx secretions are targeted by IgG in healthy individuals (Fig E1). These results demonstrate that human IgG may opsonize a wide range of nasopharynx microbiota under homeostatic conditions. 16S rRNA sequencing of IgG-bound

bacteria allowed identification of their taxonomy (Fig E3A). We observed that the IgG⁺ fraction have reduced alpha diversity (Shannon index) comparatively to the IgG⁻ fraction (Fig E3B), suggesting that IgG bind selectivity to their target and are less polyreactive than IgA. The beta diversity based on Bray-Curtis distance was also significantly different in terms of both abundance and presence/absence of different OTUs (Fig E3C). IgG⁺ fraction exhibited a significant decrease in binding in different genera, especially from *Proteobacteria* phylum (*Betaproteobacteria*, *Campylobacteriales*, *Enterobacteriales*, *Pseudomonadales*) (Fig E3D). Members of *Proteobacteria* phylum are reported to be weak inducers of systemic IgG responses⁵ and we found that IgG bind weakly to genera from *Proteobacteria* in nasopharynx of healthy individuals. Using the double binding with IgA and IgG antibodies we observed that about 54% of nasopharynx bacteria are double SIgA⁺IgG⁺ coated, and the level of IgG-only coated is low (16%) (Fig E3E, F). This data suggest that 77% of microbiota normally coated by SIgA are also coated with IgG, demonstrating a convergence of IgA and IgG responses toward the same microbial targets under homeostatic conditions. Sequencing of flow sorted IgG⁺SIgA⁻ and SIgA⁺IgG⁻ bacteria (Fig E3G) showed that alpha diversity (Shannon index) (Fig E3H) and beta diversity (based on Bray-Curtis distance) (not showed) were not significantly different between IgG⁺SIgA⁻ and SIgA⁺IgG⁻ fractions. We observed only a small enrichment on *Bacteroidetes* on IgG-only coated fraction (Fig E3I). Previous studies showed that human and mice IgG recognized *Bacteroides* that belongs to this phylum⁷. However, we conclude that IgG recognizes a diverse array of both nasopharynx pathobionts and commensal bacteria⁷. SIgADef patients have an increased anti-commensal IgG response associated with reduced systemic inflammation⁵, our results are consistent with the notion that IgG may provide a layer of mucosal protection during IgA deficiency.

Immunoglobulin (IgG) replacement therapy (IVIg) has been used extensively in the treatment of primary and secondary immunodeficiency diseases. With IVIg therapy, X-linked agammaglobulinaemia (XLA-BTK) patients (characterized by a near-complete lack of Igs) have a significant reduction in the occurrence of respiratory tract infections and these patients may live a relatively healthy life⁹. We next studied the immunoglobulins coating of nasopharynx microbiota in IVIg treated XLA-BTK patients. XLA-BTK patients lack IgA, IgM and IgD nasopharynx microbiota binding (Fig 2A). On the other hand, IVIg therapy restore the secretion of nasopharynx IgG (not shown) and enhances IgG nasopharynx microbiota binding (Fig 2A). However, despite this increase in IgG coating, XLA-BTK patients exhibit nasopharyngeal microbiota dysbiosis. The beta diversity based on Bray-Curtis distance was significantly different in terms of both abundance and presence/absence of

different OTUs (Fig 2B) and have also a low alpha microbial diversity (Shannon index) comparatively to healthy individuals (Fig 2C). XLA-BTK patients exhibited a significant enrichment in *Proteobacteria* phyla (Fig 2D) and different pathobiont genera, especially *Streptococcus* (and *Streptococcus pneumoniae* specie, not shown), *Moraxella*, *Alloiococcus*, *Bacteroides*, mucus-degrading *Mucispirillum* among others commensals (Fig 2F). For example, IgG bind weakly to genera from *Proteobacteria* phylum in healthy (Fig E3D), suggesting that the lack of IgA/IgD binding (Fig 1F)⁴ contributes to the *Proteobacteria* phyla expansion in XLA BTK patients. These results suggest that IVIg (IgG) therapy can not fully control pathobiont (e.g. *S. pneumoniae*) carriage load in nasopharyngeal cavity of XLA-BTK patients. Our results suggest an incomplete efficacy of IVIg (IgG) therapy in these patients (that may be related to the absence of IgA and IgM/IgD in these preparations) which raises the subsequent risk of recurrent sinus and respiratory tract infections⁹. However, the present study is consistent with a protective role of IgG antibodies in the nasopharyngeal mucosa in the context of IgA, IgM and IgA deficiency. IVIg therapy can help in control respiratory infections in primary immunodeficiency diseases patients by promoting pathogens opsonization, inducing complement activation and activation of Fc receptors for IgG if the opsonized bacteria reach the epithelium or the circulation to disseminate to systemic organs. However, these patients might also benefit from prophylactic IgA administration.

Pedro Goncalves, PhD^{a,b},

Bruno Charbit, MSc^c

Christelle Lenoir MSc^d,

the Milieu Interieur Consortium

Darragh Duffy, PhD^{b,c,e}

Alain Fischer MD, PhD^{d,f,g,h}

James P Di Santo, MD, PhD^{a,b}

From ^aInnate Immunity Unit, Institut Pasteur, Paris, France; ^bInstitut National de la Santé et de la Recherche Médicale (INSERM) U1223, Paris, France; ^cCenter for Translational Research, Institut Pasteur, Paris 75015, France; ^dInstitut National de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Paris, France; ^eLaboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Paris 75015, France; ^fUniversity Paris Descartes Sorbonne Paris Cité, Imagine Institut, Paris, France; ^gDepartment of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital,

Assistance Publique-Hôpitaux de Paris (APHP), Paris, France; ^hCollège de France, Paris, France. E-mail: james.di-santo@pasteur.fr

We thank the X-linked agammaglobulinaemia (XLA-BTK) patients and healthy donors that provided samples used in this study. We thank the members of Biomics NGS platform of the Institut Pasteur, Sean Kennedy and Laurence Motreff for microbial sequencing, and Amine Ghazlane and for the assistance with the data analysis. We thank members of the Di Santo laboratory for discussions. Labex Milieu Intérieur ANR 10-LBX-69-01 MI (<http://www.milieuinterieur.fr/en>) funded this study and the researcher P. Gonçalves. This study was also partially supported by grants from the Institut Pasteur, INSERM, and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (695467 - ILC_REACTIVITY).

REFERENCES

1. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, et al. Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals. *MBio*. 2015; 6:e00037.
2. Chen K, Cerutti A. New insights into the enigma of immunoglobulin D. *Immunological Reviews* 2010; 237:160-79.
3. Jorgensen SF, Holm K, Macpherson ME, Storm-Larsen C, Kummen M, Fevang B, et al. Selective IgA deficiency in humans is associated with reduced gut microbial diversity. *J Allergy Clin Immunol* 2019; 143:1969-71 e11.
4. Fadlallah J, El Kafsi H, Sterlin D, Juste C, Parizot C, Dorgham K, et al. Microbial ecology perturbation in human IgA deficiency. *Sci Transl Med* 2018; 10.
5. Fadlallah J, Sterlin D, Fieschi C, Parizot C, Dorgham K, El Kafsi H, et al. Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. *J Allergy Clin Immunol* 2019; 143:1575-85 e4.
6. Nielsen SCA, Roskin KM, Jackson KJL, Joshi SA, Nejad P, Lee JY, et al. Shaping of infant B cell receptor repertoires by environmental factors and infectious disease. *Sci Transl Med* 2019; 11.
7. Schickel JN, Glauzy S, Ng YS, Chamberlain N, Massad C, Isnardi I, et al. Self-reactive VH4-34-expressing IgG B cells recognize commensal bacteria. *Journal of Experimental Medicine* 2017; 214:1991-2003.

8. Kobayashi K, Ogata H, Morikawa M, Iijima S, Harada N, Yoshida T, et al. Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids. *Gut* 2002; 51:169-76.
9. Micol R, Kayal S, Mahlaoui N, Beaute J, Brosselin P, Dudoit Y, et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable *Haemophilus influenzae* in patients with hypogammaglobulinemia. *J Allergy Clin Immunol* 2012; 129:770-7.

FIGURE LEGENDS

FIG. 1. Nasopharynx IgD recognize a broad spectrum of pathobionts/commensals. **A**, Double binding of IgD and SIgA antibodies to nasopharynx microbiota. **B**, The antibody binding to microbiota is highly variable between healthy subjects ($n = 12$). **C**, Strategy for the BugFACS and 16S rRNA sequencing ($n = 4$). **D**, The alpha diversity, calculated using the Shannon index, in different sorted fractions. Mean and standard error of mean (SEM) values are indicated, and subgroups are compared with a nonparametric Mann-Whitney test. **E**, Principal coordinate analysis (PCoA) of 16S RNA sequencing Operational Taxonomic Units (OTU) of $\text{IgD}^+\text{SIgA}^-$ and $\text{SIgA}^+\text{IgD}^-$ sorted fraction along the first two principal coordinate (PC) axes based on Bray-Curtis distance. **F**, Differential abundance analysis showing taxa at phylum/class/order/family/genus level which it is found to be overrepresented in the $\text{IgD}^+\text{SIgA}^-$ comparably to $\text{SIgA}^+\text{IgD}^-$ fraction.

FIG. 2. Immunoglobulin (IgG) replacement therapy (IVIg) “restore” the IgG binding to pathobionts/commensals but did not rescue the nasopharynx microbiota dysbiosis of X-linked agammaglobulinemia (XLA BTK) patients. **A**, The IgG binding to nasopharynx microbiota in healthy controls ($n = 12$) and X-linked agammaglobulinemia (XLA BTK) patients under immunoglobulin (IgG) replacement therapy ($n = 5$). Median values are indicated. **B**, Principal coordinate analysis (PCoA) of 16S RNA sequencing Operational Taxonomic Units (OTU) of the healthy controls and XLA BTK patients along the first two principal coordinate (PC) axes based on Bray-Curtis distances and the respective PERMANOVA test. **C**, The alpha diversity, calculated using the Shannon index, in healthy and XLA BTK patients. Mean and standard error of mean (SEM) values are indicated, and subgroups are compared with a nonparametric Mann-Whitney test. **D**, **E**, Bar plot showing % of microbiota phylum (**D**) and genus (**E**) level in healthy and XLA BTK patients. **F**, Volcano plot displaying differential nasopharynx microbiota genus between XLA BTK patients and healthy. The vertical axis (y-axis) corresponds to the mean expression value of $\log_{10}$ (q-value), and the horizontal axis (x-axis) displays the $\log_2$ fold change value. The red dots represent the up-regulated genus in XLA BTK patients; the blue dots represent the genus downregulated. Positive x-values represent up-regulation and negative x-values represent down-regulation.

Journal Pre-proof

FIG. E1. A, Gating strategy for the microbiota flow cytometric assay. We used the DNA dye SYBR Green to preferentially stain microbes allowing us to gate on (SYBR^{hi}). We then used specific secondary antibodies to characterize the anti-commensal antibody (IgA, IgM, IgD and IgG) response. **B,** The antibody binding to microbiota is highly variable between healthy subjects (n = 12) and X-linked agammaglobulinemia (XLA-BTK) patients under immunoglobulin (IgG) replacement therapy (n = 5). Median values are indicated, and subgroups are compared with a nonparametric Mann-Whitney test.

FIG. E2. Nasopharynx SIgA binds a broad spectrum of pathobionts/commensals.

A, Strategy for the IgA-BugFACS and 16S rRNA sequencing. **B,** Principal coordinate analysis (PCoA) of 16S RNA sequencing Operational Taxonomic Units (OTU) of IgA⁺ and IgA⁻ sorted fraction along the first two principal coordinate (PC) axes based on Bray-Curtis distance and the respective PERMANOVA test. **C,** The alpha diversity, calculated using the Shannon index, in IgA⁺ and IgA⁻ sorted fraction. Mean and standard error of mean (SEM) values are indicated, and subgroups are compared with a nonparametric Mann-Whitney test. **D,** Bar plot showing % of microbiota phylum in IgA⁺ and IgA⁻ sorted fraction. **E,** Bar plot showing % of microbiota genus in IgA⁺ and IgA⁻ sorted fraction. Data are representative of 4 healthy individuals.

FIG. E3. Nasopharynx IgG recognize a broad spectrum of pathobionts/commensals. A, Strategy for the IgG-BugFACS sorting (n = 4). **B,** The alpha diversity, calculated using the Shannon index, in IgG⁺ and IgG⁻ sorted fraction. Mean and standard error of mean (SEM) values are indicated, and subgroups are compared with a nonparametric Mann-Whitney test. **C,** Principal coordinate analysis (PCoA) of 16S RNA sequencing Operational Taxonomic Units (OTU) of IgG⁺ and IgG⁻ sorted fraction along the first two principal coordinate (PC) axes based on Bray-Curtis distance and the respective PERMANOVA test. **D,** Differential abundance analysis showing taxa at phylum/order/genus level which it is found to be downrepresented in the IgG⁺ comparably to IgG⁻ fraction. **E,** Double binding of SIgA and IgG antibodies to nasopharynx microbiota. **F,** The antibody binding to microbiota is highly variable between healthy subjects (n = 12). **G,** Strategy for the BugFACS and 16S rRNA sequencing (n = 4). **H,** The alpha diversity, calculated using the Shannon index, in different sorted fractions. Mean and standard error of mean (SEM) values are indicated, and subgroups are compared with a nonparametric Mann-Whitney test. **I,** Differential abundance analysis

showing taxa at phylum/class/order level which it is found to be overrepresented in the
IgG⁺SIgA⁻ comparatibly to SIgA⁺IgG⁻ fraction.

METHODS

Patient recruitment, sample collection and processing

Nasopharynx specimens were obtained with sterile dry swabs (COPAN LQ Stuart Transport Swab; COPAN Italia S.p.A, Brescia, Italy), which are rotated five times around the inside of each nostril while applying constant pressure. Nasopharynx swabs were collected in the office under strict aseptic conditions with sterile gloves and instrumentation. Laboratory protocols were standardized and staff members were trained in sample preparation protocols¹. All swabs will be frozen (-80°C) upon collection from healthy individuals at local site. The 12 healthy donors were recruited originally as part of the *Milieu Intérieur* cohort¹ (BioTrial, Rennes, France), but were technically excluded from the main cohort due to blood sampling criteria. The clinical study was approved by the Comité de Protection des Personnes - Ouest 6 (Committee for the protection of persons) on 13 June 2012 and by the French Agence Nationale de Sécurité du Médicament (ANSM) on 22 June 2012. The study is sponsored by the Institut Pasteur (Pasteur ID-RCB Number: 2012-A00238-35) and was conducted as a single center study without any investigational product. The protocol is registered under ClinicalTrials.gov (study# NCT01699893). X-linked agammaglobulinemia patients were recruited at Hôpital Necker-Enfants Malades (French National Reference Center for Primary Immunodeficiencies). Pathogenic mutations in the Bruton tyrosine kinase (BTK) were identified in all 5 cases. At diagnosis, they had IgG plasma levels below 100 mg/ml with no detectable IgA and IgM, while all 5 had no detectable blood B cells (CD19⁺). At time of study, patients were aged 14 to 28 years (median 15). They were receiving regular IgG substitution with a trough level above 800 mg/dl (800 to 1385). None had antibiotic therapy. Two are perfectly healthy while 3 have minimal bronchiectasis. Most recent immunological investigations were unremarkable apart for the absence of detectable B cells. The age and gender is not significantly different between X-linked agammaglobulinemia patients and healthy. Written informed consent was obtained from all patients and/or parents. The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Nasopharynx swabs processing

Swabs were thawed and vortexed for 1 minute at 2500 rpm to insure complete sample recovery. Samples were transferred in a 96 well deep-well plate and centrifuged at 16.000g for 10 minutes at 4°C to pellet cells and accompanying microbes. Supernatants were recovered and stored at -80°C until analysis using a TECAN Evo 75 robot.

Bacterial Flow Cytometry

Bacterial species-specific antibody against microbiota were assessed by a flow cytometry assay was described previous². Briefly, the bacterial pellet was washed and resuspended in flow cytometry buffer (1x-PBS, 2% BSA, 0.02% w/v sodium azide) with SYBR Green (1/10000 (v/v) dilution, Invitrogen) incubated 30 min on ice. After, bacterial suspension was washed twice and pelleted by centrifugation at 16.000g for 10 min. Supernatant was removed and pellets were resuspended in 100 µL flow cytometry buffer with mouse anti-human IgA-PE (clone IS11-8E10), anti-human IgD-PerCP-Cy5.5 (clone IAG-2), anti-human IgM-APC (clone SA-DA4) and anti-human IgG-BUV395 (clone G18-145) at a final IgG concentration of 10 µg/mL in a 96-well V-bottom plate and incubated for 20 min on ice. Suspensions were washed once with 100 uL of flow cytometry buffer and cells pelleted by centrifugation, then resuspended in flow cytometry buffer with DAPI (Life Technologies) prior to flow cytometry. Acquisition of cells events was performed using a FACS LSRFortessa (Becton Dickinson, Franklin Lakes, NJ, USA) and analysis was performed with Flow-Jo software software (TreeStar, Ashland, OR). Staining of live bacteria was visualized by gating on SYTO BC⁺FSC⁺SSC⁺ DAPI cells.

BugFACS

Different immunoglobulin-binding microbiota were sorted³ (purity $\geq$ 99%) using a FACS Aria II (BD Biosciences) into eppendorf tube in a laminar flow biocontainment hood (BioProtect IV Safety Cabinet, Baker Co.). The gating strategies used to collect different bacterial populations are shown in Fig. E1. Threshold settings were set to the minimal allowable voltage for sidescatter (SSC). Isolated bacteria were pelleted (15.000×g, 10 minutes, 4 °C) and frozen at -80°C before sequencing of bacterial 16S rRNA genes.

Bacterial DNA isolation and 16S rDNA sequencing

In our study, we are performing the extraction of total genomic DNA from swabs samples, using the TECAN Freedom EVOware workstation, and the NucleoSpin® 96 Genomic DNA kit (Macherey-Nagel ®). For DNA extraction, a "negative" control was included containing buffers. Briefly, the pellets that remain in the deep well plate were incubated with Ready-Lyse™ Lysozyme Solution (250 U/µl) (Epicentre, Hessisch Oldendorf, Germany) for 30 minutes at 37°C. Next, we incubated the suspension with Proteinase K/buffer T1 working solution at 55°C overnight until the samples are completely lysed. We add 20 µg of glycogen (DNA carrier) and we follow the DNA extraction kit protocol. Finally

we eluted the DNA in 25 µl and the DNA box is immediately frozen at -80°C at local center until its use. The concentration of extracted DNA is determined using TECAN (QuantiFluor® ONE dsDNA System, Promega), and DNA integrity and size were also confirmed with the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). The V3-V4 region of the bacterial 16S rRNA region were PCR amplified with V3-340F (CCTACGGRAGGCAGCAG) and V4-805R (GGACTACHVGGGTWTCTAAT) containing a primer linker, primer pad, unique 8-mer Golay barcode which was used to tag PCR products from respective samples and negative control. PCR reactions consisted of 18 µl of AccuPrime Pfx SuperMix (12344-040; Invitrogen), 0.5 µl of each primers and 1 µl of DNA (10 ng). PCR was carried out as follows: 95 °C for 2 min, 30 cycles of 95 °C for 20 s, 55 °C for 15 s and 72 °C for 1 min, and a final extension step at 72 °C for 10 min on a Biorad thermocycler. PCR products were cleaned using NucleoMag magnetic purification beads (MACHEREY-NAGEL Kit) following the protocol, quantified with the QuantiFluor® ONE dsDNA kit (Promega), and pooled in equal amounts of each PCR product. Library pools were loaded at 12pM with a 15% PhiX spike for diversity and sequencing control, onto a v3 300-bp paired end reads cartridge for sequencing on the Illumina MiSeq NGS platform.

Sequence processing and statistical analysis

After removing reads containing incorrect primer or barcode sequences and sequences with more than one ambiguous base, we recovered from 53 samples a total of 3.090.252 reads (58.307 reads on average). The bioinformatics analysis was performed as previously described⁴. Briefly, amplicons were clustered into operational taxonomic units (OTU) with VSEARCH (v1.4) and aligned against the SILVA database. The input amplicons were then mapped against the OTU set to get an OTU-abundance table containing the number of reads associated with each OTU. The normalization, statistical analyses and multiple visualization were performed with SHAMAN (SHiny application for Metagenomic Analysis (shaman.c3bi.pasteur.fr) based on R software.

Statistical analysis

GraphPad Prism was used for statistical analysis. Thus, non-parametric tests (Mann Whitney U-test) were used where applicable.

METHOD REFERENCES

1. Thomas S, Rouilly V, Patin E, Alanio C, Dubois A, Delval C, et al. The Milieu Interieur study An integrative approach for study of human immunological variance. *Clinical Immunology* 2015; 157:277-93.
2. Moor K, Fadlallah J, Toska A, Sterlin D, Balmer ML, Macpherson AJ, et al. Analysis of bacterial-surface-specific antibodies in body fluids using bacterial flow cytometry. *Nat Protoc* 2016; 11:1531-53.
3. Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. *Cell* 2014; 158:1000-10.
4. Quereda JJ, Dussurget O, Nahori MA, Ghoulane A, Volant S, Dillies MA, et al. Bacteriocin from epidemic *Listeria* strains alters the host intestinal microbiota to favor infection. *Proceedings of the National Academy of Sciences of the United States of America* 2016; 113:5706-11.

Author: The Milieu Intérieur Consortium[†].

[†] The Milieu Intérieur Consortium[¶] is composed of the following team leaders: Laurent Abel (Hôpital Necker), Andres Alcover, Hugues Aschard, Kalla Astrom (Lund University), Philippe Bousso, Pierre Bruhns, Ana Cumano, Caroline Demangel, Ludovic Deriano, James Di Santo, Françoise Dromer, Gérard Eberl, Jost Enninga, Jacques Fellay (EPFL, Lausanne), Odile Gelpi, Ivo Gomperts-Boneca, Milena Hasan, Serge Herberg (Université Paris 13), Olivier Lantz (Institut Curie), Claude Leclerc, Hugo Mouquet, Sandra Pellegrini, Stanislas Pol (Hôpital Cochin), Antonio Rausell (INSERM UMR 1163 – Institut Imagine), Lars Rogge, Anavaj Sakuntabhai, Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Frédéric Tangy, Antoine Toubert (Hôpital Saint-Louis), Mathilde Trouvier (Université Paris 13), Marie-Noëlle Ungeheuer, Matthew L. Albert (In Situ)[§], Darragh Duffy[§], Lluís Quintana-Murci[§],

[¶] unless otherwise indicated, partners are located at Institut Pasteur, Paris

[§] co-coordinators of the Milieu Intérieur Consortium

Additional information can be found at: <http://www.pasteur.fr/labex/milieu-interieur>